Table of Contents

company-logo

Celyad Oncology SA, a clinical-stage biopharmaceutical company, focuses on the discovery and development of chimeric antigen receptor T (CAR-T) cell therapies for the treatment of cancer. Its lead product candidates include CYAD-101, an allogeneic CAR-T candidate that is in Phase 1b clinical trial for the treatment of metastatic colorectal cancer; CYAD-211, a short hairpin RNA (shRNA)-based allogeneic CAR-T candidate, which is in Phase 1 clinical trial to treat relapsed / refractory multiple myeloma; and CYAD-02, an autologous CAR-T candidate that is in Phase 1 clinical trial for the treatment of relapsed or refractory acute myeloid leukemia and myelodysplastic syndromes. The company's preclinical candidate includes CYAD-203, a non-gene edited allogeneic CAR-T candidate to co-express the cytokine interleukin-18 with natural killer group 2D ligands (NKG2D) for the treatment of solid tumors. It has licensing agreement with Novartis International AG regarding the United States patents related to allogeneic CAR-T cells; and research and development collaboration, and license agreements with Horizon Discovery Group plc for the use of its shRNA technology to generate second non-gene-edited allogeneic platform. The company was formerly known as Celyad SA and changed its name to Celyad Oncology SA in June 2020. Celyad Oncology SA was founded in 2004 and is headquartered in Mont-Saint-Guibert, Belgium.

Celyad Oncology Dividend Announcement

• Celyad Oncology does not currently offer dividends, we're keeping a close eye on its growth potential and financial developments.
• Stay tuned for updates on Celyad Oncology dividend policy and future announcements. In the meantime, explore other dividend-yielding opportunities on our website.

Celyad Oncology Dividend History

Celyad Oncology Dividend Yield

Celyad Oncology current trailing twelve-month (TTM) dividend yield is -%. Interested in purchasing Celyad Oncology stock? Use our calculator to estimate your expected dividend yield:

Celyad Oncology Financial Ratios

P/E ratio-2.44
PEG ratio12.76
P/B ratio5.78
ROE-162.02%
Payout ratio0.00%
Current ratio3.59
Quick ratio3.59
Cash Ratio2.58

Celyad Oncology Dividend FAQ

Does Celyad Oncology stock pay dividends?
Celyad Oncology does not currently pay dividends to its shareholders.
Has Celyad Oncology ever paid a dividend?
No, Celyad Oncology has no a history of paying dividends to its shareholders. Celyad Oncology is not known for its dividend payments.
Why doesn't Celyad Oncology pay dividends?
There are several potential reasons why Celyad Oncology would choose not to pay dividends to their shareholders:

1. Growth opportunities: Companies, especially in fast-growing industries like technology, reinvest earnings into expansion, R&D, or acquisitions to fuel future growth and increase company value.

2. Tax implications: Not paying dividends can reduce the tax burden on shareholders, who may prefer to defer taxes until selling shares and realizing capital gains.

3. Investor preferences: Some investors prefer companies to reinvest profits for higher long-term returns, particularly those seeking capital appreciation over income.

4. Capital allocation priorities: Companies may allocate cash to pay down debt, fund share buybacks, or invest in projects with higher returns than dividends.

5. Market expectations: In certain sectors, like technology, reinvesting profits for growth and innovation is often prioritized over distributing dividends to shareholders.
Will Celyad Oncology ever pay a dividend?
The decision for a company to pay dividends depends on various factors including its financial performance, growth prospects, capital allocation priorities, and shareholder preferences. While Celyad Oncology has not paid dividends historically and has instead focused on reinvesting its earnings for growth, it's ultimately up to the company's management and board of directors to decide whether to initiate a dividend policy in the future.
Is Celyad Oncology a dividend aristocrat?
Celyad Oncology is not considered a Dividend Aristocrat. The term "Dividend Aristocrat" is typically used to describe a company in the S&P 500 index that has increased its dividend payouts for at least 25 consecutive years.
Is Celyad Oncology a dividend king?
Celyad Oncology is not classified as a "Dividend King". A Dividend King is a company that has managed to increase its dividend payouts for 50 consecutive years or more, which is an even more selective group than the Dividend Aristocrats.
Is Celyad Oncology a dividend stock?
No, Celyad Oncology is not considered a dividend stock. A dividend stock is a stock of a company that regularly pays out dividends to its shareholders.
How to buy Celyad Oncology stocks?
To buy Celyad Oncology you need a brokerage account. Open an account with a reputable brokerage firm that offers access to the stock market. Consider factors such as fees and account minimums.

Place an order: Use the brokerage's trading platform to place an order to buy Celyad Oncology stock.

Remember that buying stocks involves risk, and it's important to carefully consider your investment goals, risk tolerance, and conduct thorough research before making any investment decisions.